Testing effectiveness (Phase 2)Study completedNCT00055770
What this trial is testing
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Who this might be right for
Recurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the Larynx+19 more
National Cancer Institute (NCI) 45